Roche

Roche reports that divarasib reduced the risk of death by 44 percent versus available therapies from Amgen and Bristol Myers Squibb in a late‑stage clinical trial and that fewer patients discontinued treatment due to side effects. Divarasib targets the KRAS G12C mutation and is intended as an oral therapy to become a standard treatment for a specific form of lung cancer. Roche is conducting additional late‑stage studies, evaluating use in earlier disease stages and combinations with Keytruda, and has raised expected peak sales to 2–3 billion CHF. » More on finanzen.net

In an interim analysis of the phase‑III Imagination study, the investigational drug Sefaxersen reduced proteinuria by 43.1% versus placebo after 37 weeks, a statistically significant effect. The effect was observed across all predefined patient subgroups, and the safety profile matched the phase‑II results with no new safety signals. The study will continue to assess kidney function over two years; Sefaxersen is intended as a monthly subcutaneous self‑injection. » More on finanzen.net

Roche reports positive interim results from the phase‑III study of sefaxersen in IgA nephropathy: after 37 weeks proteinuria fell by a statistically significant 43.1 percent versus placebo. The effect was seen across all predefined patient groups and no new safety signals were identified. The Imagination study will continue to assess kidney function over two years. Sefaxersen is designed as a monthly subcutaneous self‑injection. » More on finanzen.net